Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Mohawk Industries heads into its October 29 earnings report with a fresh analyst downgrade landing on the same day short interest climbs to its highest level in over a month, a collision of signals that makes the setup unusually charged.
The most immediate news is the RBC Capital move. Analyst Mike Dahl downgraded MHK to Underperform from Sector Perform this morning, cutting his price target from $130 to $112, roughly 11% below the current price of $126.05. That is a meaningful break from his August position, when he raised his target to $130 after the Q2 print. Also this week, Melius Research initiated coverage with a Buy rating and a $188 target. The contrast could not be sharper: the Street is pulling in opposite directions. The consensus sits at Hold across 10 analysts, with one Underperform, and the mean target is $137.87. That target is above the current price, but the direction of travel matters. Most of the target-raising activity followed the Q2 beat in early August, when multiple firms lifted numbers. Since then, Evercore ISI has trimmed its target twice, and now RBC has cut its rating entirely. The post-earnings enthusiasm has started to fade.
Short interest reinforces the cautious tilt. At 8.1% of the free float, the short book is not extreme, but it has grown fast. Shares short have risen 39% over the past month, one of the sharper build-ups in the stock's recent history. The pace accelerated from early September, when short interest was running near 3.7 million shares, to the current 5.0 million. The borrow market remains loose. Availability is running at roughly 944% of short interest, meaning there are nearly ten shares available to lend for every one already borrowed, so the cost to borrow a fresh short position is negligible at 0.44%. This is not a squeeze setup. It is a slow, deliberate accumulation of bearish bets at low cost.
Options positioning has also shifted. The put/call ratio closed at 0.71 on Tuesday, above its 20-day average of 0.61. That is not an extreme reading, the 52-week high is 1.43, but the ratio has drifted higher through late September and early October, tracking the same cautious direction as the short book. The ORTEX short score, at 54.1, is in moderate territory and has been largely flat over the past two weeks. Nothing here signals panic, but the aggregate lean is negative.
Valuation gives the bears some cover. The stock trades at roughly 12.6 times trailing earnings and 0.8 times book, both modest multiples for an industrials name. However, the price-to-book multiple has fallen about 6% over the past month alongside a 5.7% decline in the share price. EPS momentum over the past 30 days ranks in just the 32nd percentile, though the 90-day figure sits at the 74th and the forward earnings growth score is near the top of the universe at the 98th percentile. The bull case rests on that forward growth thesis: the company has guided for improved volumes and productivity gains, and after years of margin pressure from input costs and weak housing demand, analysts who stayed positive through the downturn are betting on a normalisation cycle. The bear case, and the RBC downgrade fits squarely here, is that residential renovation demand remains weak, the consumer is stretched, and the stock has already priced in a recovery that is arriving slowly.
The founder's chair is worth a note. Jeffrey Lorberbaum, still the largest individual holder with 14.2% of shares, sold roughly $1.5 million worth of stock on September 16 across a series of small open-market transactions. None were filed under a 10b5-1 plan, making them discretionary sales. The new CEO, Paul De Cock, received an award of 30,000 shares on September 30, a compensation grant rather than an open-market purchase. Net insider activity over the past 90 days is a sell of approximately $22.4 million, the bulk of it from Lorberbaum. The founder still holds a dominant stake, so the sales are not alarming in isolation, but the net direction is outward.
Recent earnings reactions give the Q4 setup additional weight. The July 30 print produced a 1-day gain of 8.6% and a 5-day gain of 16.8%, one of the strongest post-results moves the stock has seen in recent quarters. With the next report due October 29, three weeks away, the question is whether the fundamental picture has held up since that upside surprise, or whether the analyst downgrades and short build-up reflect something more structural. Wikipedia attention is running more than two standard deviations above its 90-day average, a sign retail interest has picked up alongside the analyst debate, making the October 29 print a focal point worth tracking carefully.
See the live data behind this article on ORTEX.
Open MHK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
